LLMs and Real-World Evidence: Extracting Structure From Clinical Text

Real-world evidence (RWE) initiatives frequently stumble on the same hurdle: the vast majority of clinical detail remains buried in unstructured text. While structured electronic health record fields capture basic billing codes and laboratory values, critical clinical nuance lives in oncology consultation notes, pathology narratives, discharge summaries, and registry entries. Manual chart abstraction has long been the default strategy to bridge this gap, but it is notoriously slow, expensive, and difficult to scale across multi-site studies. Large language models (LLMs) present a compelling alternative for automated or semi-automated text processing, provided data science teams approach them as specialized extraction pipelines rather than autonomous clinical experts.

Unstructured Text as the RWE Bottleneck

In typical observational studies, valuable clinical variables, such as ECOG performance status, specific reasons for treatment discontinuation, or subtle disease progression markers, are rarely found in neat database tables. Human abstractors traditionally read through narrative notes, interpret ambiguous phrasing, and log variables into electronic data capture platforms. This human process is expensive and subject to fatigue, leading to variability across abstractors and sites.

LLMs excel at parsing complex, unformatted natural language and converting it into structured outputs. Teams building RWE pipelines use these models to parse heterogeneous document types, including semi-structured pathology reports and free-text physician notes. Rather than relying on simple keyword matching, modern LLMs process context, recognizing when a clinical term refers to a patient's historical family background, a ruled-out diagnosis, or an active primary condition.

From Free Text to Standardized Ontologies

Extracting raw phrases is only the first step; RWE studies require normalized parameters mapped to standard medical ontologies. Converting unstructured text into standardized concepts like SNOMED CT, ICD-10, RxNorm, or MedDRA enables downstream statistical analysis and regulatory submissions.

A core technical challenge in clinical entity extraction is resolving contextual nuance. A note stating that a patient denies shortness of breath after starting therapy contains terms that keyword search engines might misinterpret as an active symptom. LLMs can handle negation, hypothetical scenarios, and complex temporal relationships with mixed reliability — performance varies by model, prompt, and record type, and has to be measured on your own data. That includes determining whether an adverse event occurred during the primary index window or years prior. Teams commonly structure these pipelines by instructing the LLM to extract the targeted clinical entity alongside its context, temporal anchor, and confidence rationale, before mapping the entity to a controlled vocabulary via specialized normalization models or vector search.

Verification Frameworks and Inter-Rater Metrics

Deploying LLMs for clinical abstraction requires rigorous validation frameworks analogous to those used for human abstraction teams. Operating leaders should establish benchmark evaluation sets composed of double-abstracted historical charts verified by clinical subject matter experts.

To evaluate LLM performance effectively, teams measure traditional information retrieval metrics, including precision, recall, and F1 scores at the variable level. Additionally, evaluating agreement using metrics such as Cohen's kappa or Gwet's AC1 between the LLM and expert human abstractors offers direct insight into consistency. In the error reviews teams describe, recurring patterns frequently point back to ambiguities in the original clinical text or poorly specified extraction guidelines rather than intrinsic model failure. Establishing a robust human-in-the-loop review workflow, where lower-confidence model outputs or discordances between parallel extraction pipelines are routed to human abstractors, ensures high data quality while preserving operational speed.

Data Governance and Infrastructure Boundaries

Processing protected health information (PHI) or sensitive patient narratives through third-party LLMs introduces substantial data privacy and regulatory considerations. RWE operating teams must establish clear infrastructure boundaries before ingesting sensitive datasets.

Deploying models within dedicated virtual private clouds, utilizing on-premise instances, or establishing strict zero-data-retention enterprise API contracts are common approaches to safeguard patient data. Life-science organizations must carefully review their specific vendor agreements, as generic commercial terms often fail to meet institutional data privacy requirements. Furthermore, teams must recognize that software infrastructure and model features may support, but do not satisfy, regulatory compliance or GxP validation requirements. Ultimate responsibility for data integrity, patient privacy, and regulatory adherence resides with the study sponsor and its internal quality oversight units.

Why Protocol Design Dictates Success

It is tempting to view LLMs as a magical layer that eliminates the need for careful study design. In practice, an extraction pipeline is only as good as the underlying study protocol and variable dictionary. If a protocol fails to clearly define what constitutes a valid line of therapy or disease recurrence, an LLM will produce inconsistent outputs, much like a confused human abstractor.

Before writing prompts or fine-tuning models, research teams must craft precise, unambiguous abstraction rules. These rules must define the clinical criteria, acceptable narrative evidence, handling of missing data, and temporal boundaries for every targeted variable. The study protocol remains the definitive source of truth. When the protocol clearly defines variables, LLM pipelines can be engineered with precise system prompts, strict output schemas, and automated validation rules. In an RWE context, AI serves as an accelerator for well-defined protocol execution, not a substitute for rigorous epidemiological methodology.

Implementing a Pragmatic Extraction Strategy

Organizations adopting LLMs for RWE should avoid all-or-nothing implementations. A pragmatic approach begins with high-value, lower-risk targets: extracting unambiguous discrete variables, such as biomarker laboratory results or specific surgical procedures, before tackling complex subjective endpoints like clinical response assessments.

By pairing structured output constraints, such as JSON Schema or Pydantic validation, with continuous quality audits and expert clinical sampling, operating leaders can scale chart abstraction throughput while maintaining strict quality standards. Any adoption strategy must be reviewed against institutional standard operating procedures, data protection policies, and quality management systems to ensure alignment with institutional standards and regulatory expectations.

How it works in practice

• What data goes in. De-identified clinical narrative text — progress notes, discharge summaries, pathology and radiology reports — held inside the governed environment, together with the target ontology or common data model the output must land in.
• What the model predicts or ranks. Structured fields extracted from free text: diagnoses, staging, biomarker status, therapy lines, dates and outcomes, each mapped to a coded term rather than left as a string.
• Technique or model family. Named-entity recognition and relation extraction models for the narrow, high-volume fields, and large language models in a retrieval-augmented, span-citing configuration for the fields that need context across a whole note.
• How it is trained or validated. Against a human-annotated gold-standard sample drawn from the same source system, reported as precision, recall and F1 per field, with inter-rater agreement measured on the human annotations first so the model is not held to a standard the humans do not meet.
• What the team does with the output. Extracted fields feed the analysis dataset with provenance back to the source span, and any field below its accuracy threshold is routed to manual abstraction instead of being used. The study protocol, not the extraction run, defines what counts as evidence.
• A representative example. Input: an oncology progress note. Output: stage IIIB, EGFR exon 19 deletion positive, second-line therapy start date, each with the quoted sentence attached. An abstractor spot-checks a sampled share of records; fields that fail the sample are re-abstracted by hand.

Sources

1. Real-World Evidence — U.S. Food and Drug Administration.
2. OMOP Common Data Model — Observational Health Data Sciences and Informatics.
3. MedDRA — Medical Dictionary for Regulatory Activities — ICH MedDRA Maintenance and Support Services Organization.